Apr 19, 2022
John Glasspool is the CEO of Anthos Therapeutics, a clinical stage biopharmaceutical company focused on high-risk cardiovascular and metabolic diseases. Anthos is developing innovative therapies for treating thrombosis or more commonly known as clots that are caused by a stroke or heart attack. The current agents, while protecting from a clot, also cause more frequent bleeding. The main unmet need is to give protection from the clots while not having the patient bleed.
John explains, “People that are at risk of these are elderly people who obviously have some changes in the dynamics of their vessels. The other area that’s of particular common occurrence is in patients undergoing cancer. And even, in fact, the development of a clot sometimes is the first sign for patients with cancer in their disease prognosis and diagnosis.”
“We’re developing a factor XI agent. In fact, it’s a dual activity factor XI and XIa. What that really means from a patient perspective is we believe that we can pharmacologically uncouple the prevention of your pathological thrombosis, your clot, and yet leave intact your normal hemostasis. If you have a bleed, you clot normally, but we don’t increase the bleeding by interfering with normal hemostasis. In our ideal world, and we need to prove this clinically, the drug is still in development, we stop clots while not increasing bleeding.”
@Anthos_Tx #Abelacimab #Anticoagulant #Thrombosis #Hemostasis
